Evidence map›Paper›PMID 32718715›Full record

ReviewMedicina clinica2020

[Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection].

Valeria Herrera-Lasso Regás, María Teresa Dordal Culla, Ramón Lleonart Bellfill

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicina clinica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Observational
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Valeria Herrera-Lasso RegásUnitat d'Al·lergologia Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, España. Electronic address: vherreralasso@gmail.com.
María Teresa Dordal CullaUnitat d'Al·lergologia Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, España.
Ramón Lleonart BellfillUnitat d'Al·lergologia Servei de Medicina Interna, Hospital Universitari de Bellvitge, Barcelona, España.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, there is no treatment approved for COVID-19. Numerous drugs are being used in an empirical manner according to experience and availability. Studies demonstrating their efficacy and safety are still to be published. Thus, it is of vital importance for healthcare workers to be well informed and updated regarding possible immunological and non-immunological adverse effects regarding such treatments. In this narrative revision, the rationale use of these treatments in the SARS-CoV-2 infection is emphasized as well as their most frequently described adverse drug reactions. Drugs that are being essayed to counteract both clinical phases that are thought to take place in the severe stage of this disease are included; an initial phase where a viral infection prevails and a second phase where an inflammatory response takes over. Adverse reactions registered in the Pharmacovigilance Program of our hospital before the onset of this pandemic have also been included.

Indexed as

COVID-19 Drug TreatmentAnti-Inflammatory AgentsAntiviral AgentsHumansPharmacovigilanceTreatment OutcomeAnti-Inflammatory AgentsAntiviral AgentsAdverse drug reactionAlergia a medicamentoCOVID-19COVID-19 treatmentDrug allergyReacción adversa a medicamentoSARS-CoV-2Tratamiento COVID-19

Identifiers

PMID32718715
PMCPMC7346774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.